Skip to main content
Quest Diagnostics

Development and Validation of a High-throughput LC-MS/MS Method for Routine Monitoring of Benzodiazepines in Serum

ADLM 2026

Association for Diagnostics and Laboratory Medicine

Anaheim, CA, June 26-30, 2026,

Poster presentation: Development and Validation of a High-throughput LC-MS/MS Method for Routine Monitoring of Benzodiazepines in Serum

Authors: Thomas W Gorewich, Michael P Smith, Taylor J Hunt, Sarah H Bartock

Medical Specialty: Prescription Drug Monitoring, Toxicology

Related content

Conference Presentation
The Determination of Mitragynine in Human Urine by Liquid Chromatography Tandem Mass Spectrometry
Conference Presentation
Comparison of Benzodiazepine Positivity Rates in Serum and Urine Specimens by LC-MS/MS in a Clinical Laboratory Setting
Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing
Test FAQ
Pain Management Antipsychotics With Confirmation Serum and Urine
Publication
Trends in Urine Cotinine Concentrations Among Adolescents Who Vape Nicotine

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.